Using 2-aminobenzimidazole derivatives to inhibit Mycobacterium smegmatis biofilm formation
- 12 February 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (3) , 456-459
Abstract
Biofilm formation by mycobacteria can lead to enhanced antibiotic tolerance. Herein, we report on the identification of a series of 2-aminobenzimidazole (2-ABI) derivatives that potently inhibit biofilm formation by Mycobacterium smegmatis.Keywords
Funding Information
- National Institutes of Health (AI106733)
This publication has 16 references indexed in Scilit:
- Genome-Wide Transcriptome Profiling of Mycobacterium smegmatis MC2 155 Cultivated in Minimal Media Supplemented with Cholesterol, Androstenedione or GlycerolInternational Journal of Molecular Sciences, 2016
- Expression of antimicrobial drug tolerance by attached communities ofMycobacterium tuberculosisPathogens and Disease, 2014
- Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilmsExpert Review of Anti-infective Therapy, 2012
- Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput ScreeningACS Chemical Biology, 2012
- Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatmentBulletin of the World Health Organization, 2008
- Quorum-sensing inhibitors as anti-pathogenic drugsInternational Journal of Medical Microbiology, 2006
- Understanding biofilm resistance to antibacterial agentsNature Reviews Drug Discovery, 2003
- Biofilms: Survival Mechanisms of Clinically Relevant MicroorganismsClinical Microbiology Reviews, 2002
- Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilmsNature, 2000
- The Emergence of Drug-Resistant Tuberculosis in New York CityNew England Journal of Medicine, 1993